

## **Zeuzem, Stefan, Prof. Dr.**

Date of Birth 19.03.1959 in Frankfurt a.M., Germany

Department of Medicine  
Goethe University Hospital  
Theodor-Stern-Kai 7  
60590 Frankfurt a.M.  
Tel.: +49 (0)69 6301 4544  
E-Mail: zeuzem@em.uni-frankfurt.de

Position Professor C4/W3  
Children 3 children

### **1) Academic Education**

1978-1985 Medical education at the University of Frankfurt a.M., Newcastle upon Tyne, UK, and Cambridge, UK

### **2) Advanced Professional Degrees**

1986-1999 Medical specialization in Internal Medicine, Gastroenterology, Endocrinology, Intensive Care Medicine  
1992 Habilitation, University of Frankfurt a.M.  
1986 Doctoral-thesis, University of Frankfurt a.M. (*summa cum laude*)  
1985 Approbation as Medical Doctor  
1985 Final Medical Examination

### **3) Positions Held**

since 2007 Professor of Medicine (W3/C4), Director Department of Medicine, University Hospital Frankfurt a.M.  
2002-2007 Professor of Medicine (C4), Director Department of Medicine II, Saarland University Hospital  
1998-2002 Associate Professor, Department of Medicine, University Hospital Frankfurt  
1993-2002 Junior Faculty, Department of Medicine, University Hospital Frankfurt  
1993 Postdoctoral Researcher, Howard Hughes Medical Institute, Yale University Medical School, USA  
1990-1991 DFG-research scholarship, Max-Planck-Institute for Biophysics, Frankfurt a.M.  
1985-1986 Military Service, Giessen Military Hospital

### **4) Other Activities**

#### ***Honors and Awards***

Since 2010 Member of the Medical Committee of the German Council for Science and Humanities (Medizinausschuss des Wissenschaftsrats)  
2010-2016 Member of the German Council for Science and Humanities (Wissenschaftsrat)  
2009-2012 Member of the Senate Committee for Clinical Research of the German Research Foundation (DFG)  
2004-2010 Member of the Senate Committee for Graduate Schools of the German Research Foundation (DFG)  
1998 Theodor-Stern-Award  
1993 Thannhauser Prize, German Society for Gastroenterology (DGVS)  
1987 Research Prize, German Diabetes Society

#### ***Other Professional Activities***

2019 President (elect) German Society for Digestive and Metabolic Diseases (DGVS)  
since 2016 Associate Editor of *Gastroenterology*  
2010-2016 Board Member German Society for Digestive and Metabolic Diseases (DGVS)  
since 2010 Editorial Advisory Board *Nature Reviews Gastroenterology and Hepatology*  
2010-2014 Associate Editor *Journal of Hepatology*

- 2007-2014 Speaker of the BMBF-Cluster “Host and viral determinants for susceptibility and resistance to hepatitis C virus infection”
- 2004-2013 Speaker of DFG-Clinical Research Group “Mechanisms of resistance development and optimisation of antiviral strategies”

#### **Memberships in Societies (selected)**

- American Association for the Study of Liver Diseases (AASLD)
- European Association for the Study of the Liver (EASL)
- German Society for Digestive and Metabolic Diseases (DGVS)
- German Society for Internal Medicine (DGIM)
- German Cancer Association (DKG)

#### **5) Publications - 10 important out of > 910, H-index: >120**

1. Hindie V, Stroba A, Zhang H, Lopez-Garcia LA, Idrissova L, **Zeuzem S**, Hirschberg D, Schaeffer F, Jørgensen TJ, Engel M, Alzari PM, Biondi RM. Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. *Nat Chem Biol* 2009;5:758-764.
2. **Zeuzem S**, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Böcher WO, Mensa FJ. Faldaprevir and deleobuvir for HCV genotype 1 infection. *N Engl J Med* 2013;630-639.
3. Janssen HL, Reesink HW, Lawitz EJ, **Zeuzem S**, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. *N Engl J Med* 2013;368:1685-1694.
4. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, **Zeuzem S**, Trebicka J, Bernardi M, Arroyo V. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology* 2013;144:1426-1437.
5. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, **Zeuzem S**, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *JAMA* 2012;308:2584-2593.
6. **Zeuzem S**, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011;364:2417-2428.
7. **Zeuzem S**, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, Svarovskaia E, Dvory-Sobol H, Doehle B, Hedskog C, Yun C, Brainard DM, Knox S, McHutchison JG, Miller MD, Mo H, Chuang WL, Jacobson I, Dore GJ, Sulkowski M. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. *J Hepatol* 2017;66:910-918.
8. Ibrahim AA, Schmithals C, Kowarz E, Köberle V, Kakoschky B, Pleli T, Kollmar O, Nitsch S, Waidmann O, Finkelmeier F, **Zeuzem S**, Korf HW, Schmid T, Weigert A, Kronenberger B, Marschalek R, Piiper A. Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1 $\alpha$  and Epithelial-Mesenchymal Transition. *Clin Cancer Res* 2017;23:3896-3905.
9. Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Ledinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, **Zeuzem S**. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. *N Engl J Med* 2017; 376:2134-2146.
10. **Zeuzem S**, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. *N Engl J Med* 2018;378:354-369.

**Patents:** Presently 3 patents in the areas of biomarkers and molecular diagnostics.